We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-c... Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Show more
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth...
AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr...
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1534 | -4.40804597701 | 3.48 | 3.565 | 3.2 | 6208 | 3.4104662 | CS |
4 | 0.2266 | 7.30967741935 | 3.1 | 3.6299 | 2.51 | 23312 | 3.03267411 | CS |
12 | -1.9934 | -37.469924812 | 5.32 | 5.34 | 2.51 | 23515 | 3.72633084 | CS |
26 | -1.6534 | -33.2008032129 | 4.98 | 5.65 | 2.49 | 36410 | 3.84164577 | CS |
52 | -2.0689 | -38.3449170605 | 5.3955 | 6.75 | 2.3087 | 66223 | 4.13081769 | CS |
156 | -87.4234 | -96.3343250689 | 90.75 | 95.85 | 2.3087 | 429473 | 25.83582628 | CS |
260 | -58.7734 | -94.6431561997 | 62.1 | 158.1 | 2.3087 | 505246 | 43.98937604 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions